Merck & Co Inc (MRK)

MRK (NYSE:Drugs)
$57.63
pos +0.83
+1.46%
Today's Range: 56.56 - 57.80 | MRK Avg Daily Volume: 11,144,100
Last Update: 12/17/14 - 4:02 PM EST
Volume: 12,663,821
YTD Performance: 13.49%
Open: $57.05
Previous Close: $56.80
52 Week Range: $47.61 - $62.20
Oustanding Shares: 2,850,873,371
Market Cap: 162,357,238,478
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 6
Moderate Buy 0 0 0 0
Hold 6 6 6 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.00 2.00 2.08
Latest Dividend: 0.45
Latest Dividend Yield: 3.16%
Dividend Ex-Date: 12/11/14
Price Earnings Ratio: 30.95
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
30.95 31.20 24.99
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-5.32% 18.11% 56.69%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.80 -0.04 -0.01
Net Income -28.30 3.60 0.65
EPS -26.70 4.32 0.74
Earnings for MRK:
EBITDA 14.65B
Revenue 44.03B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $0.86 $0.78 $3.49 $3.58
Number of Analysts 8 1 12 12
High Estimate $0.88 $0.78 $3.51 $3.75
Low Estimate $0.83 $0.78 $3.46 $3.26
Prior Year $0.88 $0.88 $3.49 $3.49
Growth Rate (Year over Year) -1.99% -11.36% 0.02% 2.41%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Reams of stocks make sense on a pullback. And what looks bad? Anything even remotely connected to oil and gas.
This market is a good team facing a tough opponent on the road.
This market will let us know what to do next.
But stay disciplined, honor your stops and protect gains.
Investing in safer hospital stays.
Approval of malaria vaccine could provide a shot in the arm.

Upcoming Dividend Attractions Real Money Pro($)

Some old friends and some false friends.

Buy Gilead Sciences Real Money Pro($)

Its prospects exploded with a breakthrough drug.
Bullish
Nov 18, 2014 | 7:22 AM EST
MRK estimates were raised through 2017, Morgan Stanley said. Company can deliver higher Vytorin/Zetia sales. Equal-weight rating and ne...
The U.S. markets and economy are unique.

Columnist Conversations

AAPL needs to clear this hurdle IF this last low is any good!! View Chart » ...
The Fed didn't raise interest rates, but the market did via lower bond and note prices. The recent run in Trea...
WHR has regained all the of the ground lost over the last nine sessions during today's rip higher. The st...
Just to let you know, the three dissents come from governors who will not be voting members in 2015. Fisher i...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.